271 related articles for article (PubMed ID: 9450554)
41. Crystal structure of the urokinase receptor in a ligand-free form.
Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
[TBL] [Abstract][Full Text] [Related]
42. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer.
Rasch MG; Lund IK; Almasi CE; Hoyer-Hansen G
Front Biosci; 2008 May; 13():6752-62. PubMed ID: 18508692
[TBL] [Abstract][Full Text] [Related]
43. Regulation of integrin function by the urokinase receptor.
Wei Y; Lukashev M; Simon DI; Bodary SC; Rosenberg S; Doyle MV; Chapman HA
Science; 1996 Sep; 273(5281):1551-5. PubMed ID: 8703217
[TBL] [Abstract][Full Text] [Related]
44. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
45. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
Jo M; Thomas KS; Wu L; Gonias SL
J Biol Chem; 2003 Nov; 278(47):46692-8. PubMed ID: 12963722
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
47. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
48. Novel interactions between urokinase and its receptor.
Shliom O; Huang M; Sachais B; Kuo A; Weisel JW; Nagaswami C; Nassar T; Bdeir K; Hiss E; Gawlak S; Harris S; Mazar A; Higazi AA
J Biol Chem; 2000 Aug; 275(32):24304-12. PubMed ID: 10801829
[TBL] [Abstract][Full Text] [Related]
49. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
Int J Cancer; 1994 Sep; 58(6):877-81. PubMed ID: 7927882
[TBL] [Abstract][Full Text] [Related]
50. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
[TBL] [Abstract][Full Text] [Related]
51. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.
Leduc D; Beaufort N; de Bentzmann S; Rousselle JC; Namane A; Chignard M; Pidard D
Infect Immun; 2007 Aug; 75(8):3848-58. PubMed ID: 17517866
[TBL] [Abstract][Full Text] [Related]
52. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor.
Andolfo A; English WR; Resnati M; Murphy G; Blasi F; Sidenius N
Thromb Haemost; 2002 Aug; 88(2):298-306. PubMed ID: 12195704
[TBL] [Abstract][Full Text] [Related]
53. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains.
Behrendt N; Ronne E; Dano K
J Biol Chem; 1996 Sep; 271(37):22885-94. PubMed ID: 8798468
[TBL] [Abstract][Full Text] [Related]
54. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
[TBL] [Abstract][Full Text] [Related]
55. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
56. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology.
List K; Høyer-Hansen G; Rønne E; Danø K; Behrendt N
J Immunol Methods; 1999 Jan; 222(1-2):125-33. PubMed ID: 10022379
[TBL] [Abstract][Full Text] [Related]
57. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
58. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
59. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
60. Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins.
Chavakis T; May AE; Preissner KT; Kanse SM
Blood; 1999 May; 93(9):2976-83. PubMed ID: 10216093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
